K Ras News Today

Patients with metastatic colorectal cancer who have the KRAS G12C mutation demonstrated improved quality of life following sotorasib and panitumumab compared with standard therapy.

A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.

Experts address the impact of platinum shortages, 4-cycle platinum chemotherapy, and available treatments beyond platinum chemotherapy.

Advisers to the US Food and Drug Administration on Thursday found that data from a late-stage trial of Amgens Lumakras could not be relied on.

It becomes the second KRAS-targeted therapy for use in patients with non–small cell lung cancer (NSCLC) whose tumors have this mutation.